Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

Fitness Influencer Banned From TikTok After Sparking Backlash For Harmful Dieting Advice

“What about all those influencers that promote obesity? Why aren’t their accounts being shut down?” The post Fitness Influencer Banned From TikTok After Sparking Backlash For Harmful Dieting Advice first appeared on Bored Panda.

Bored Panda

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Fortune

Severe obesity is on the rise in the US

Obesity is high and holding steady in the U.S. About 4 in 10 Americans have obesity overall and about 1 in 10 have severe obesity

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Roll Call

Health and productivity losses from obesity ‘far outstrip weight-loss jab costs’

Exclusive: £100bn-a-year cost of obesity to UK makes clear economic case for use of drugs such as Ozempic, says report

The Guardian - UK

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Barchart

Council adopts ‘compassionate’ approach to obesity and rejects weight-loss goals

The council rejects the principle that a certain weight equals healthiness

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Mental health overtakes cancer and obesity as Britons’ biggest health worry

Ipsos survey asked people in 31 countries what they thought of their health and healthcare

The Guardian - UK

Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Investors Business Daily

New blood test could be an early warning for child diabetes – study

Scientists say that testing for fatty acids could make it easier to identify children at risk of various conditions.

The Independent UK

TRUTH in Labeling Act would heighten the warning for shoppers looking to cut sugar, salt and saturated fat intake

With rising rates of obesity in the U.S. and increasing attention being paid to the health harms of processed foods, it’s clear that far more could be done to help consumers make healthy food choices.

The Conversation

How we think about ‘obesity’ and body weight is changing. Here’s why

From doctors’ offices to family gatherings, larger-bodied people report being bombarded with unsolicited advice about their eating and exercise habits. The underlying message? They “just need to lose weight” to fix almost any health problem.

The Conversation

Childhood obesity linked to schizophrenia in adulthood: study

Having more than the normal range of body mass index (BMI) in childhood could elevate the risk of developing schizophrenia in adulthood, the study revealed.

Medical Daily

FDA hopes to fight obesity with labels

The agency plans to make a formal proposal in October

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

StockNews.com

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

Evening Standard

Junk food ads to be banned pre-watershed from next year

The Guardian - UK

NHS restricting access to obesity services across England, BMJ finds

Budget cuts to local services fell disproportionately on care for obese patients, leading to ‘postcode lottery’

Get all your
news in one place.

100’s of premium titles.
One news app.

Newcastle Herald

'Removing blame': New weight-loss drug for obesity and overweight people

First there was Ozempic, then Wegovy, now we have Mounjaro.

Evening Standard

Liraglutide: Weight loss drug found to be 'safe and effective' for children aged under 12

Daily injection found to reduce body mass index and improve blood pressure in children between ages of 6 and 12

The Independent UK

Weight-loss drug Saxenda effective for kids as young as 6, study shows

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

The Independent UK

Ozempic and Wegovy can supercharge weight loss and even defy ageing – but can they save the NHS?

Analysis: It’s been heralded as the ‘fountain of youth’ that could cure heart problems and promote rapid weight loss, but could Ozempic change all our lives, asks Rebecca Thomas

Investors Business Daily

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Medical Daily

Obesity Raises Risk Of COVID Infection By 34%: Study Says

The study suggests that obesity not only worsens the outcomes of COVID but also increases the risk for infection upon exposure.

International Business Times

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

1 … 10 11 12 13

People

Lars Fruergaard Jørgensen

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.